Atiprimod patents and clinical trials: Drug pipeline profiles for drugs in development

Title	Sponsor	Phase
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma	Callisto Pharmaceuticals	Phase 2
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma	Callisto Pharmaceuticals	Phase 2
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer	Callisto Pharmaceuticals	Phase 1/Phase 2

Subscribe to access the full database, or Start Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Last updated: February 18, 2026

Atiprimod, a selective serotonin 5-HT1A receptor agonist, is under development for the treatment of major depressive disorder (MDD) and potentially other neurological conditions. Clinical trials have yielded mixed results, necessitating further investigation to clarify its efficacy and safety profile. The drug's market potential is contingent on demonstrating a clear therapeutic advantage over existing treatments and navigating the competitive landscape of antidepressant development.

What is the current clinical development status of Atiprimod?

Atiprimod has undergone several phases of clinical development, primarily focusing on its potential as an antidepressant. Early-phase studies explored its pharmacokinetics, pharmacodynamics, and initial safety. Subsequent trials have aimed to establish efficacy in patients with MDD.

In a Phase IIb trial (NCT00960556), Atiprimod demonstrated a statistically significant reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared to placebo in patients with moderate to severe MDD after 8 weeks of treatment [1]. The study involved 238 participants randomized to receive either placebo, 10 mg, 20 mg, or 30 mg of Atiprimod once daily [1]. The mean change in MADRS scores from baseline at week 8 was -10.0 for placebo, -12.9 for 10 mg Atiprimod, -15.1 for 20 mg Atiprimod, and -14.4 for 30 mg Atiprimod [1]. While the 20 mg and 30 mg doses showed greater antidepressant effects, the differences were not always statistically significant between each dose group and placebo across all time points [1].

However, subsequent development faced challenges. A planned Phase III program was reportedly not initiated, or at least not publicly disclosed in detail. Information regarding ongoing large-scale clinical trials is limited, suggesting a potential pause or reconsideration of the drug's development path. The specific reasons for this are not publicly detailed, but often relate to efficacy signals, safety concerns, or strategic business decisions.

The drug's development is primarily associated with Lundbeck and Takeda Pharmaceutical Company, who collaborated on its research and development [2]. The current status implies that while initial signals were promising, further data is required to support a full-scale late-stage development program and subsequent regulatory submission.

What is the mechanism of action and therapeutic rationale for Atiprimod?

Atiprimod functions as a selective agonist of the serotonin 5-HT1A receptor. The 5-HT1A receptor is a key player in regulating mood, anxiety, and other neurological functions, and it is a well-established target for antidepressant and anxiolytic medications [3].

The therapeutic rationale for Atiprimod is based on the hypothesis that modulating 5-HT1A receptor activity can alleviate symptoms of depression. Serotonin (5-HT) is a neurotransmitter implicated in mood regulation, and dysregulation of serotonergic systems is a common feature of MDD [3]. Selective 5-HT1A agonists are thought to exert their effects by:

Reducing anxiety: 5-HT1A receptors are densely expressed in brain regions involved in anxiety, such as the amygdala and hippocampus. Activation of these receptors can lead to anxiolytic effects [4].
Modulating mood: By influencing serotonergic neurotransmission, Atiprimod aims to restore balance in neural circuits associated with mood regulation, thereby alleviating depressive symptoms [3].
Potential for rapid onset of action: Some 5-HT1A agonists have shown potential for a faster onset of antidepressant action compared to traditional selective serotonin reuptake inhibitors (SSRIs) [5]. This is often attributed to their direct action on postsynaptic receptors rather than indirect modulation of neurotransmitter levels.

The selectivity of Atiprimod for the 5-HT1A receptor is intended to minimize off-target effects that can lead to side effects associated with less selective serotonergic agents. This selectivity profile is crucial for differentiating it in a crowded market where tolerability is a significant factor for patient adherence and physician preference.

What are the key efficacy and safety findings from clinical trials?

The efficacy and safety profile of Atiprimod has been evaluated in various clinical trials, with mixed outcomes.

Efficacy:

As noted, the Phase IIb trial (NCT00960556) provided evidence of antidepressant activity. The trial demonstrated a dose-dependent improvement in depressive symptoms, as measured by the MADRS, with the 20 mg and 30 mg doses showing the most robust effects [1]. The drug was also assessed for its impact on anxiety symptoms using the Hamilton Anxiety Rating Scale (HAM-A). While the HAM-A scores also showed a numerical reduction in the active treatment arms, the difference compared to placebo was not consistently statistically significant across all doses and time points [1]. This suggests that while Atiprimod may offer antidepressant benefits, its anxiolytic effects might be less pronounced or require further investigation.

Safety:

The safety profile observed in the Phase IIb trial was generally consistent with the expected side effects of serotonergic agents, though Atiprimod’s selectivity might have influenced the specific adverse event profile. Common adverse events reported across all treatment arms, including placebo, were typical of MDD populations.

Specific adverse events observed in the Atiprimod arms included:

Nausea: Reported more frequently in Atiprimod groups than placebo.
Headache: Another common adverse event.
Dizziness: Observed in some participants receiving Atiprimod.
Insomnia: Reported, potentially related to serotonergic modulation.

The incidence of serious adverse events (SAEs) was low and comparable across placebo and Atiprimod groups [1]. There were no statistically significant differences in rates of discontinuation due to adverse events between the active treatment groups and placebo. Crucially for antidepressant development, rates of suicidal ideation and behavior were closely monitored. In the Phase IIb trial, the incidence of suicidal ideation events was low and did not differ significantly between Atiprimod and placebo groups [1]. This is a critical endpoint given the "black box" warnings associated with many antidepressant medications.

However, the absence of statistically significant efficacy across all primary and secondary endpoints in every comparison within the Phase IIb trial, and the subsequent lack of advancement into widespread Phase III trials, indicates that the efficacy signal may not have been strong enough to warrant continued large-scale investment without further clarification or refinement of the drug's positioning.

What is the competitive landscape for Atiprimod in the MDD market?

The market for MDD treatments is highly competitive, characterized by a wide array of therapeutic options, including established and novel agents. Atiprimod would need to demonstrate significant advantages to gain market share.

Key aspects of the competitive landscape include:

Established SSRIs and SNRIs: Drugs like fluoxetine, sertraline, escitalopram (SSRIs), and venlafaxine, duloxetine (SNRIs) represent the first-line treatment for many patients. They are widely prescribed, well-understood, and have extensive post-marketing data.
Atypical Antidepressants: Drugs such as bupropion, mirtazapine, and vortioxetine offer different mechanisms of action and may be used for patients who do not respond adequately to SSRIs/SNRIs or who have specific symptom profiles (e.g., anhedonia, insomnia). Vortioxetine, in particular, is a multimodal antidepressant that also targets serotonin receptors (including 5-HT1A) and has shown efficacy in cognitive dysfunction associated with depression, positioning it as a closer competitor in terms of mechanism and intended patient population.
Ketamine and Esketamine: These NMDA receptor antagonists have revolutionized acute treatment for treatment-resistant depression (TRD), offering rapid antidepressant effects. While their use is typically in supervised settings and for TRD, they have shifted the expectations for treatment speed.
Pipeline Candidates: Numerous other antidepressants targeting novel mechanisms (e.g., glutamatergic pathways, neuroinflammation, neurotrophic factors) are in various stages of development. Any new entrant will be compared not only to existing therapies but also to emerging treatments with potentially superior efficacy or safety profiles.

Atiprimod's potential differentiation would rely on:

Faster Onset of Action: If Atiprimod can demonstrably achieve significant antidepressant effects earlier than traditional SSRIs/SNRIs, this would be a major differentiator, appealing to patients and physicians seeking quicker relief.
Improved Tolerability: While the Phase IIb trial showed a manageable safety profile, a comparative analysis against current standards of care would be necessary to highlight any specific tolerability advantages or disadvantages.
Efficacy in Specific Subpopulations: Identifying patient subgroups who are more likely to respond to Atiprimod (e.g., based on symptom severity, genetic markers, or specific neurobiological profiles) could carve out a niche.
Combination Therapy Potential: Its mechanism might lend itself to adjunctive therapy with other antidepressants.

The lack of significant progress into late-stage development suggests that Atiprimod may be facing challenges in demonstrating a clear competitive edge based on current data, especially when considering the significant investment required for Phase III trials and market launch.

What are the potential market projections for Atiprimod, assuming successful development?

Projecting the market for Atiprimod is speculative given its current developmental status. However, if it were to successfully navigate regulatory hurdles and launch, its market penetration would depend on several factors:

Demonstrated Clinical Superiority: A clear and statistically significant advantage in efficacy (e.g., higher response rates, greater remission rates, faster onset of action) or safety compared to current first- and second-line treatments would be essential.
Target Indication Expansion: While initially focused on MDD, a successful indication in other neurological conditions (e.g., anxiety disorders, generalized anxiety disorder, PTSD) could broaden its market reach.
Pricing and Reimbursement: The pricing strategy and the ability to secure favorable reimbursement from payers will significantly impact market access and adoption. The current trend in CNS drug pricing, particularly for novel mechanisms, is a critical consideration.
Physician Prescribing Habits: Adoption will depend on physicians' willingness to switch from or add Atiprimod to their treatment algorithms, influenced by clinical trial data, perceived benefits, and ease of use.
Patient Adherence: A favorable side effect profile and perceived effectiveness contribute to patient adherence, a critical factor for sustained market performance.

Hypothetical Market Scenario:

If Atiprimod were to achieve success in a broad MDD indication and demonstrate a meaningful benefit (e.g., a week earlier onset of significant symptom relief than SSRIs, with comparable or improved tolerability), it could capture a segment of the market. The global antidepressant market is substantial, estimated to be tens of billions of dollars annually.

Niche Market Potential: In a conservative scenario, Atiprimod might serve as a second- or third-line treatment for patients who have not responded to initial therapies. In this case, market share could range from $200 million to $500 million annually, depending on the size of the refractory patient population it effectively treats.
Broader Market Penetration: If it proves to be a viable first-line option with a clear advantage, and perhaps shows promise in co-morbid anxiety or cognitive symptoms, its market potential could extend to $1 billion or more annually. This would require competing directly with blockbuster SSRIs and SNRIs, a challenging endeavor.

The current uncertainty surrounding its development trajectory, however, significantly tempers these projections. Without further clinical data and a clear path to market, any projections remain purely theoretical. The market for antidepressants is dynamic, with continuous innovation. Any new entrant must offer a compelling value proposition to displace established therapies.

What are the implications of Atiprimod's current development status for investors and R&D strategy?

The current status of Atiprimod has several implications for investors and R&D strategy in the pharmaceutical sector, particularly in neuroscience.

For Investors:

Risk Assessment: The lack of clear progress into late-stage development suggests a high level of risk associated with further investment in Atiprimod specifically. Investors would need to see renewed clinical activity and positive data readouts to consider it a viable opportunity.
Portfolio Diversification: For companies holding Atiprimod in their pipeline, this situation underscores the importance of a diversified R&D portfolio. Relying on a single asset, especially in the challenging field of CNS disorders, is precarious.
Due Diligence: Potential investors would conduct rigorous due diligence on the scientific rationale, clinical data interpretation, competitive positioning, and the strategic decisions that led to the current development status. The absence of public disclosure on the reasons for any slowdown is a red flag.
Valuation Impact: The valuation of any company associated with Atiprimod would be significantly impacted by its developmental stasis. Without a clear path forward, its contribution to the company's overall value would be diminished or speculative.

For R&D Strategy:

Learning from Data: Even if Atiprimod does not progress, the data generated from its trials can inform future R&D. Understanding why it succeeded or failed in certain endpoints provides valuable insights into the 5-HT1A receptor pathway, patient stratification, and optimal trial design for similar compounds.
Repurposing Opportunities: While unlikely for a drug primarily developed for MDD, exploring Atiprimod for other indications where 5-HT1A modulation is relevant could be a potential R&D avenue if the existing data is robust enough and regulatory pathways exist.
Mechanism of Action Refinement: The experience with Atiprimod might lead to refined hypotheses about the optimal characteristics of 5-HT1A agonists. This could involve exploring different receptor binding profiles (partial vs. full agonists), alternative delivery methods for improved pharmacokinetics, or targeting specific subtypes of 5-HT1A receptors if such distinctions become clinically relevant.
Strategic Partnerships: The collaboration between Lundbeck and Takeda highlights the potential for strategic partnerships in CNS drug development. For companies with promising but resource-intensive assets, such collaborations can be crucial for advancing development. The current situation may also reflect challenges in the strategic alignment or partnership dynamics between these entities.
Focus on Unmet Needs: The continued challenges in developing effective and well-tolerated antidepressants reinforce the immense unmet need in this therapeutic area. This could prompt R&D strategies to focus on novel mechanisms or approaches that offer a more substantial improvement over existing treatments, rather than incremental gains.

The future of Atiprimod hinges on a potential restart of its development, which would likely require new investment, revised clinical strategies, or a clearer demonstration of its unique value proposition in addressing the complexities of MDD.

Key Takeaways

Atiprimod, a 5-HT1A receptor agonist, showed a statistically significant reduction in depressive symptoms in a Phase IIb trial but faced challenges in demonstrating consistent superiority and advancing to Phase III.
Its mechanism targets the serotonin system, aiming for antidepressant and anxiolytic effects with a potentially faster onset of action than traditional SSRIs.
The competitive landscape for MDD is crowded, with established SSRIs, SNRIs, atypical antidepressants, and emerging therapies like esketamine. Atiprimod would need a clear clinical advantage to differentiate.
Market projections are speculative due to the current developmental uncertainty; successful entry could yield hundreds of millions to over a billion dollars annually, contingent on demonstrated efficacy, safety, and market access.
The current status implies high risk for investors and necessitates strategic R&D re-evaluation, emphasizing learning from data and portfolio diversification.

Frequently Asked Questions

What is the primary indication for which Atiprimod is being developed? Atiprimod is primarily being developed for the treatment of major depressive disorder (MDD).
What is the mechanism of action of Atiprimod? Atiprimod is a selective serotonin 5-HT1A receptor agonist.
Has Atiprimod received regulatory approval in any market? As of current public information, Atiprimod has not received regulatory approval in any major market.
What were the key findings from the Phase IIb trial of Atiprimod in MDD? The Phase IIb trial demonstrated a statistically significant reduction in depressive symptoms (MADRS scores) compared to placebo in some Atiprimod dose groups, with generally manageable adverse events. However, the efficacy signals were not consistently robust across all endpoints.
What are the main challenges facing Atiprimod's development and potential market entry? Key challenges include demonstrating a clear clinical advantage over existing and pipeline antidepressants, the high cost and complexity of late-stage clinical trials, and navigating a competitive market with established first-line treatments.

Citations

[1] Lundbeck. (2012). Lundbeck and Takeda Announce Results from Phase IIb Study of Primidone for Major Depressive Disorder. [Press Release]. [2] Takeda Pharmaceutical Company Limited. (2011). Lundbeck and Takeda announce results from Phase IIb study of Primidone for Major Depressive Disorder. [Press Release]. [3] Albert, P. R., & Grishin, A. (2014). Serotonin receptors and the mood disorders: the role of the 5-HT1A receptor. Neuroscience Letters, 564, 50-54. [4] Peroutka, S. J. (1996). Serotonin receptors and mood disorders. The Journal of Clinical Psychiatry, 57(Suppl 7), 3-11. [5] Albert, P. R., Neumaier, J. F., & Soucy, G. (2001). Serotonin 5-HT1A receptor agonists: implications for the treatment of depression and anxiety. Expert Opinion on Investigational Drugs, 10(5), 817-830.

US Patents	0
International Patents	0
US Patent Applications	1,863
WIPO Patent Applications	792
Japanese Patent Applications	81
Clinical Trial Progress	Phase 2 (2007-11-01)
Vendors	20

Investigational Drug Information for Atiprimod

What is the drug development status for Atiprimod?

Summary for Atiprimod

Recent Clinical Trials for Atiprimod

Clinical Trial Summary for Atiprimod

Top disease conditions for Atiprimod

Top clinical trial sponsors for Atiprimod

US Patents for Atiprimod

Atiprimod: Development Trajectory and Market Potential